Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
Follow NEUP
Neuphoria Therapeutics Inc. (NEUP) EV/Sales
As of 16 October 2026, Neuphoria Therapeutics Inc. (NEUP) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −17.0× (August 2024) to 1,969× (October 2022); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | −0.1× | — |
| FY2023 | 543× | (61.42%) |
| FY2022 | 1,408× | 159.23% |
| FY2020 | 543× | 0.00% |
| FY2019 | 543× | 0.00% |
| FY2018 | 543× | 0.00% |
| FY2017 | 543× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | −0.1× | — |
| Mar 2025 | −0.4× | — |
| Dec 2024 | 2.1× | (99.61%) |
| Jun 2023 | 543× | (61.42%) |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TCRX TScan Therapeutics, Inc. compare | −5.3× |
| ATYR aTyr Pharma, Inc. compare | −3.4× |
| NEUP Neuphoria Therapeutics Inc. | −0.3× |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| DYAI Dyadic International Inc. compare | 4.0× |
| ACGN Aceragen, Inc. compare | 4.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)